Prostate Cancer Management

Risk Stratification

• The National Comprehensive Cancer Network recommends risk stratification for prostate cancer management, with options including active surveillance, surgery, radiation therapy, and hormone therapy depending on disease stage, patient age, and life expectancy 1
• Patients with very low risk prostate cancer have a Gleason score ≤6, PSA <10 ng/mL, <3 positive biopsy cores, ≤50% cancer in any core, and PSA density <0.15 ng/mL/g 1
• Patients with low risk prostate cancer have a Gleason score ≤6 and PSA <10 ng/mL 1, 2
• Patients with intermediate risk prostate cancer have a Gleason score 7, or PSA 10-20 ng/mL 1, 2
• Patients with high risk prostate cancer have a Gleason score 8-10, or PSA >20 ng/mL 1
• Patients with very high risk prostate cancer have locally advanced disease (T3b-T4) 1

Diagnostic Approach

• The European Society for Medical Oncology recommends serum PSA measurement and digital rectal examination (DRE) for patients with urinary symptoms 3, 4
• Prostate biopsy is indicated for abnormal DRE or elevated PSA, and should be performed under transrectal ultrasound guidance with a minimum of 8 cores 3, 4
• The pathology report should include Gleason score and extent of involvement 3

Treatment Options by Risk Category

• For patients with very low/low risk disease and life expectancy <10 years, observation (watchful waiting) is recommended 1, 5
• For patients with very low/low risk disease and life expectancy 10-20 years, active surveillance is recommended 1
• For patients with intermediate risk disease, options include radical prostatectomy with pelvic lymph node dissection (PLND), external beam radiation therapy (EBRT) with or without androgen deprivation therapy (ADT), and brachytherapy 1, 2, 6, 7
• For patients with high risk disease, standard treatment options include radical prostatectomy with PLND, radiation therapy plus ADT, and EBRT plus brachytherapy with or without ADT 1, 6, 7
• For patients with very high risk/locally advanced disease, treatment options include radiation therapy with long-term ADT, EBRT plus brachytherapy with or without long-term ADT, and radical prostatectomy with PLND 1, 6

Special Considerations

• The National Comprehensive Cancer Network recommends active surveillance protocol with PSA determination no more often than every 6 months, DRE no more often than every 12 months, and repeat prostate biopsy no more often than every 12 months 1
• External beam radiotherapy should use conformal techniques and a minimum target dose of 70 Gy given in 2.0 Gy fractions or equivalent 3
• Patients should be informed that ADT with radiation increases adverse effects on sexual function 6
• Older men experience higher rates of permanent erectile dysfunction and urinary incontinence after prostatectomy compared to younger men 6

Follow-up After Treatment

• After radical prostatectomy, serum PSA should be below detection level after 2 months 8, 9
• After external beam radiotherapy, serum PSA should reach 1 mg/L within 16 months 8, 9
• First follow-up visit should be at 3 months after radical treatment, and should include PSA measurement, digital rectal examination, and assessment of treatment-related symptoms 8, 9

Common Pitfalls and Caveats

• Primary ADT alone should not be used for localized prostate cancer as it does not improve survival 1
• Cryotherapy, HIFU, and focal therapy are not recommended as standard initial treatments for localized prostate cancer 1, 2
• Genetic counseling should be considered for high-risk patients with strong family history of specific cancers (breast, ovarian, pancreatic, etc.) 7
• Patients with obstructive urinary symptoms may be better candidates for surgical approaches rather than radiation 6
• Brachytherapy can exacerbate urinary obstructive symptoms 6

Definitive Management of Clinically Localized Prostate Cancer Involving the Transitional Zone and Apex

Risk Stratification and Treatment Selection

• The NCCN guidelines recommend radical prostatectomy with extended pelvic lymph node dissection or external‑beam radiation therapy (minimum 70 Gy) as definitive options for clinically localized disease involving both the transitional zone and apex, with selection based on Gleason score, PSA level, and clinical stage. 10
• For high‑risk disease (Gleason 8‑10 or PSA > 20 ng/mL), the NCCN advises either radiation plus long‑term androgen‑deprivation therapy (2–3 years) or radical prostatectomy with extended lymph‑node dissection. Evidence from both NCCN and The Journal of Urology supports this combined‑modality approach. 10, 11

Biopsy Recommendations

• Transition‑zone biopsies are not performed during the initial biopsy; they should be added to repeat‑biopsy protocols when PSA remains persistently elevated. 12
• Extended 12‑core biopsy schemes must include dedicated apical sampling, particularly the anterior apical horn (peripheral‑zone tissue), to improve cancer detection. 12, 13
• On repeat biopsy for a rising PSA, laterally directed and apical cores yield the highest cancer detection rates. 12

Surgical Management (Radical Prostatectomy)

• Radical prostatectomy is appropriate for any patient with clinically localized disease that can be completely excised, provided life expectancy is ≥10 years and there are no prohibitive comorbidities. 10
• Extended pelvic lymph‑node dissection (removing node‑bearing tissue from the external iliac vein to Cooper’s ligament) detects nodal metastases roughly twice as often as a limited dissection. 10
• Extended lymph‑node dissection may be omitted only when nomograms predict a <2 % probability of nodal metastasis. 10
• High‑volume surgeons at high‑volume centers achieve superior outcomes; laparoscopic and robot‑assisted approaches provide results comparable to open surgery when performed by experienced operators. 10
• Expected postoperative complications include erectile dysfunction in up to 80 % of patients and urinary incontinence in up to 49 % (with <5 % requiring >2 pads daily at one year). 11
• Preserving urethral length beyond the apex and avoiding injury to the distal sphincter during prostatectomy reduces the risk of postoperative urinary incontinence. 10

Radiation Therapy (External‑Beam Radiation)

• External‑beam radiation therapy should be delivered with conformal techniques at a minimum dose of 70 Gy in 2 Gy fractions (or an equivalent regimen). 10
• For high‑risk disease (T3a, Gleason 8‑10, or PSA > 20 ng/mL), radiation must be combined with androgen‑deprivation therapy for at least 2 years. 11
• Dose escalation above 70 Gy provides additional benefit for poorly differentiated (high‑grade) tumors. 11
• Target volumes include the prostate bed; irradiation of pelvic lymph nodes is optional and not mandatory. 10

Brachytherapy

• Permanent interstitial brachytherapy (≈120 Gy palladium or ≈140 Gy I‑125) is an acceptable definitive option for low‑ to intermediate‑risk disease. 14
• High‑quality implants should achieve ≥90 % of prostate volume receiving at least 100 % of the prescribed dose. 14

Post‑Treatment Surveillance (Salvage Radiotherapy)

• Salvage radiotherapy is indicated for biochemical recurrence after definitive treatment; it is most effective when the pre‑salvage PSA is <1 ng/mL. 10

Evidence‑Based Prostate Cancer Treatment Recommendations (Cited Evidence)

Low‑Risk Localized Disease (T1‑2a, Gleason ≤ 6, PSA < 10 ng/mL)

• Active surveillance provides 99 % disease‑specific survival at 8 years in patients with life expectancy > 10 years. 15
• When definitive therapy is chosen, external beam radiotherapy should be delivered with a minimum total dose of 70 Gy in 2 Gy fractions. 15

Intermediate‑Risk Localized Disease (Gleason 7 or PSA 10‑20 ng/mL)

• Radical prostatectomy and external beam radiotherapy combined with 6 months of androgen‑deprivation therapy (ADT) achieve comparable oncologic outcomes. 15
• External beam radiotherapy for this group should also use a minimum dose of 70 Gy. 15

High‑Risk Localized Disease (T3‑4, Gleason 8‑10, PSA > 20 ng/mL)

• The preferred regimen is external beam radiotherapy plus long‑term ADT for 2–3 years; this multimodal approach improves survival compared with surgery alone. 16
• Extended pelvic lymph‑node dissection during radical prostatectomy detects nodal metastases roughly twice as often as limited dissection. 16

Metastatic Prostate Cancer

• First‑line therapy consists of ADT (bilateral orchidectomy or LHRH agonist) combined with an androgen‑receptor pathway inhibitor such as abiraterone or darolutamide. 15
• Initial ADT should include an LHRH agonist plus a short‑course anti‑androgen to prevent disease flare. [15][17]
• Docetaxel administered on a 3‑weekly schedule is recommended for symptomatic castration‑refractory disease. 15
• In castration‑refractory settings, continue ADT and add second‑line hormonal agents (anti‑androgen or corticosteroid). [15][18]
• Palliative external beam radiotherapy (single 8 Gy fraction or 10 × 3 Gy) is effective for painful bone metastases. 15
• Radioisotope therapy (e.g., strontium‑89 or samarium‑153) and intravenous bisphosphonates are indicated for resistant bone pain. 15

Side‑Effect Profiles of Curative Modalities

Radical Prostatectomy

• Erectile dysfunction occurs in ~80 % of patients (versus ~45 % with watchful waiting). [15][16]
• Urinary incontinence is reported in ~49 % of patients (versus ~21 % with watchful waiting). [15][16]
• Infertility is universal after surgery. 16

External Beam Radiotherapy

• Produces lower rates of urinary incontinence than surgery but higher rates of bowel dysfunction and delayed erectile dysfunction. [15][19]
• Approximately 80 % (4 / 5) of patients maintain erections initially after radiotherapy. 19
• Bowel side‑effects include diarrhea and rectal irritation. [19][16]
• Urinary irritation (painful urination) is common, yet incontinence is less frequent than after surgery. 19

Brachytherapy

• Offers long‑term survival comparable to radical prostatectomy with fewer chronic urinary symptoms and less erectile dysfunction. 15
• About 80 % (4 / 5) of patients preserve erectile function. 19
• May exacerbate pre‑existing obstructive urinary symptoms; therefore, contraindicated in patients with significant lower urinary tract obstruction. 15

Androgen‑Deprivation Therapy (ADT)

• Causes universal loss of libido and erectile function. 16
• Associated with metabolic complications: weight gain, increased risk of osteoporosis and diabetes. 16
• Gynaecomastia can be prevented by breast‑bud irradiation (8‑10 Gy) when using bicalutamide. [15][17]
• Hot flashes are a common adverse effect of LHRH agonists. 15

Therapies Not Recommended as Standard Initial Treatment

• Cryotherapy, high‑intensity focused ultrasound (HIFU), and focal therapy lack sufficient evidence and are not advised for primary management of prostate cancer. 16